Matt Calistri | Vice President, Investor Relations |
Michel Vounatsos | Chief Executive Officer |
Michael Ehlers | Executive Vice President of Research & Development |
Jeff Capello | Chief Financial Officer |
Al Sandrock | Chief Medical Officer |
Geoff Meacham | Barclays |
Michael Yee | Jefferies |
Terence Flynn | Goldman Sachs |
Geoffrey Porges | SVB Leerink |
Cory Kasimov | JPMorgan |
Chris Raymond | Piper Jaffray |
Umer Raffat | Evercore |
Matthew Harrison | Morgan Stanley |
Ying Huang | Bank of America-Merrill Lynch |
Alethia Young | Cantor Fitzgerald |
Robyn Karnauskas | Citi |
Good morning. My name is Jack, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Fourth Quarter and Full Year 2018 Financial Results and Business Update Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session.